Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyperexcitable neurons, reduces repetitive firing, and limits the spread of epileptic activity, thereby contributing to seizure control without markedly affecting normal neuronal conduction.

The prescribing clinician determines the appropriate intravenous dose and infusion rate based on the patient’s age, weight, renal function, and overall clinical condition. Dosing is individualized and should follow the prescriber’s instructions and local guidelines.

Safety data for lacosamide in pregnancy are limited, and it is classified as having an unknown pregnancy category. Use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding considerations are similar; the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Lacosamide differs from many traditional antiepileptics, such as carbamazepine, by selectively enhancing the slow inactivation of sodium channels rather than blocking fast inactivation. This mechanism may result in a distinct side‑effect profile, with potentially lower risk of certain cognitive effects, while still providing effective seizure control in focal epilepsy.

Lacosamide Fresenius Kabi must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

The medication is supplied as a sterile injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically as a slow infusion over a prescribed period, following the dosing instructions provided by the prescriber.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation or arrhythmias, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions including anaphylaxis, emergence of suicidal thoughts or depression, and hepatic dysfunction indicated by elevated liver enzymes.

Lacosamide is contraindicated in individuals with a known hypersensitivity to lacosamide or any of its excipients. Caution is advised for patients with severe cardiac disease, significant renal or hepatic impairment, and those for whom alternative antiepileptic therapies are more appropriate.